The current status of drug-coated devices in lower extremity peripheral artery disease interventions

Amlani, Vishal; Falkenberg, Mårten; Nordanstig, Joakim

doi:10.1016/j.pcad.2021.02.002

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SELUTION SLR BTK IDE trial will debut enrollment in the U.S. and Europe this calendar year (Table 7). Sirolimus-coated balloons may provide an alternative to PCBs in other forms [100].…”

Section: Beyond Prestigementioning

confidence: 99%

Progress on developing an effective below-the-knee drug-coated balloon

Khoury¹,

Brodmann²,

Schneider³

2021

Reviews in Cardiovascular Medicine

View full text Add to dashboard Cite

Infrapopliteal atherosclerotic disease continues to present the greatest conundrum for effective endovascular therapies. To date, conventional angioplasty has been fraught with early restenosis and recoil in these complex, long, calcified, and occlusive lesions. The success of metallic drug-eluting stents in coronary arteries has not carried over to below-the-knee arteries. Initial promise in paclitaxel-coated balloons has not been demonstrated in large randomized clinical trials. Furthermore, the potential association between paclitaxel and mortality continues to generate tremendous controversy. The goal of this review article is to discuss the evolution and challenges of drugcoated balloon (DCB) science, present the clinical results of currently available tibial DCBs, and introduce new horizons in DCB technology.

show abstract

Section: Beyond Prestigementioning

confidence: 99%

Progress on developing an effective below-the-knee drug-coated balloon

Khoury¹,

Brodmann²,

Schneider³

2021

Reviews in Cardiovascular Medicine

View full text Add to dashboard Cite

show abstract

“…Although further developments and refinements of the endovascular armamentarium including drug coated devices are of obvious importance to solve the problem of restenosis, rrestenosis continues to be a major problem limiting the effectiveness of revascularization procedures [5]. Improvements in PTA techniques, stent technology should be accompanied by equal research efforts concerning stabilization/regression of the atherosclerotic plaque [6].…”

Section: Introductionmentioning

confidence: 99%